Genistein improves heart failure with preserved ejection fraction through BNIP3L-mediated mitophagy

Area of Science:

• Cardiovascular Research
• Mitochondrial Biology
• Pharmacology

Background:

• Heart failure with preserved ejection fraction (HFpEF) lacks effective treatments.
• Mitochondrial dysfunction and impaired mitophagy are key pathological mechanisms in HFpEF.
• BNIP3L is vital for maintaining cardiomyocyte energy balance via mitochondrial autophagy.

Purpose of the Study:

• To investigate the therapeutic potential of genistein in HFpEF.
• To explore genistein's impact on BNIP3L-mediated mitophagy.
• To elucidate the cardioprotective mechanisms of genistein in HFpEF.

Main Methods:

• HFpEF was induced in mice using a high-fat diet and L-NAME.
• Mice and cardiomyocytes were treated with genistein.
• Cardiac function, remodeling, and BNIP3L-mediated mitophagy were assessed.

Main Results:

• Genistein treatment significantly improved cardiac function and myocardial remodeling in HFpEF mice.
• Echocardiographic parameters, blood pressure, and exercise performance were enhanced.
• Genistein stabilized BNIP3L conformation, increased its expression, and promoted mitophagy in cardiomyocytes.

Conclusions:

• Genistein demonstrates significant cardioprotective effects in a mouse model of HFpEF.
• The mechanism involves direct interaction with BNIP3L, enhancing mitophagy.
• Genistein is a promising therapeutic candidate for treating HFpEF.